Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06836726

Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer (EVO)

Phase II Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

Sponsor: ImmunoGenesis

Conditions Castration Resistant Prostate Cancer

Interventions Evofosfamide

Updated 3 times since 2025 Last updated: Jan 27, 2026 Started: May 27, 2026 Primary completion: May 27, 2028 Completion: May 27, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06836726, this PHASE2 trial focuses on Castration Resistant Prostate Cancer and remains actively recruiting participants. Sponsored by ImmunoGenesis, it has been updated 3 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Feb 2026 — Present [monthly]

Not Yet Recruiting PHASE2
Apr 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2
Mar 2025 — Apr 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ImmunoGenesis
University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada